A PHARMACEUTICAL PREPARATION FOR TOPICAL ADMINISTRATION OF ANTIGENS AND/OR VACCINES TO MAMMALS VIA A MUCOSAL MEMBRANE

Abstract: A novel type of formulation for the topical administration of antigens and/or vaccines to mammals via mucosal membranes comprising one or more adjuvants/vehicles selected from (a) polyoxyethylene sorbitan monoesters, (b) polyoxyethylene castor oil, (c) caprylic/capric acid glycerides and (d) gangliosides in an amount of 0.01 to 15 % (v/v) calculated on the total volume of the preparation. This formulation enhances the immunological response in a mammal following mucosal administration, e.g. nasal, oral, rectal or vaginal application.

Description: A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane The present invention relates to novel pharmaceutical pre¬ parations for topical administration of antigens and/or vaccines to mammals, including humans, via a mucosal mem¬ brane. The invention also relates to the use of certain compounds (to be defined in more detail below) as adju¬ vants or vehicles in such preparations. The parenteral (intramuscular and subcutaneous) admini¬ stration of antigens and/or vaccin. is normally regarded as the most convenient way of administration. However, the administration by injection presents a range of disadvan- tages. Thus it requires the use of sterile syringes and may cause pains and irritations, particularly in the case of repeated injections, including the risk of infection. More significantly, in the case of intramuscular injec¬ tions there is also a risk of the infection being poorly tolerated. There is likely to be an induration (hardening of tissue), haemorrhage (bleeding) and/or necrosis (local death of tissue) at the injection site. Besides, injec¬ tions cannot be administered satisfactorily by untrained persons. Administration of attenuated virus, bacteria or parasites has been attempted intranasally as well as through other mucosal surfaces. The elicitation of an immune response by such antigens through mucosal surfaces cannot be consider- ed unexpected in such cases, because the modified live pathogens of the vaccine is following the natural route of infection of the wild-type pathogen creating immunity through a sub-clinical infection. The use of modified live pathogen to effect immunization entails a certain risk, however, because the more purified antigens are very poor immunogens and thus require effective formulations and adjuvants to produce a clinically protective immune re¬ sponse. Mucosal administration is currently receiving special interest, attempting to stimulate locally produced anti¬ bodies (secretory IgA antibodies) and also to avoid the inconveniences caused by the direct intervention into the organism in connection with parenteral administration. Additionally, this route of administration may convenient¬ ly be used as an alternative to parenteral injection, since it may well be performed by an untrained person. Furthermore, small children will avoid the psychological irritation during injection (vaccination). In order to be an attractive alternative to parenteral administration, the intranasal administration should be capable of stimulating humoral and cellular immune factors both systemically (mainly of the IgG isotype) and at muco- sal surfaces where most pathogens enter the host by lo¬ cally produced antibodies of the secretory IgA (IgAs) isotype. Several oral vaccines have been shown to induce appropriate IgA responses in remote secretions including saliva, lachrymal fluid and fluids obtained from nasal and gastrointestinal washes. Such intranasally administered vaccines and/or antigens may not cause any considerable pain or irritation to the patient nor any irreversible damage or irritation to the mucosal surfaces. In nasal administration, the antigen and/or vaccine must be applied to the mucosa in such a condition that it is able to penetrate or to be absorbed through the mucosa. In order to penetrate the mucus the vehicle must be biocom- patible with the mucus and hence have a certain degree of hydrophilicity. Vaccines and/or antigens are not able to be administered in pure form. It is necessary to blend them with other components to obtain a preparation which is ready for use. Dependent on the chemical properties of the antigen and/or vaccine it will be necessary to take various considera¬ tions into account before a pharmaceutical preparation for humans or animals can be produced. It has now surprisingly been found that the topical ad- ministration of antigens and/or vaccines to mammals via mucosal membranes can be performed in a new and signifi¬ cantly improved manner by using a novel type of formula¬ tion, said preparation being characterized by comprising one or more adjuvants/vehicles selected from (a) polyoxyethylene sorbitan monoesters of the general formula H 2 C(0C 2 H 4>z R wherein R is selected among laurate, palmitate, stearate and oϊeate, and wherein the sum of w, x, y and z is 4, 5 or 20; (b) polyoxyethylene castor oil produced by reacting 1 mole of castor oil or hydrogenerated castor oil with 10-45 moles of ethylene oxide; (c) caprylic/capric acid glycerides of the general formula R 1 -0-CH 2 -CH-CH 2 -0-R 1 OR 1 wherein each R 1 independently is H or a C O -C, Q acyl group containing 1-6% free glycerol, 45-50% monogly- cerides, 30-40% diglycerides and 5-9% triglycerides, and (d) gangliosides of the general formula R 2 -Gal-Glc-Cer R -NeuAc wherein Gal is galactose, Glc is glucose, Cer is ceramide (N-fatty acyl sphingosine) and NeuAc is N- acetyl neuraminic acid (sialic acid), and wherein R 2 may be one or more substances selected among N-acetyl galactosamine, galactose, N-acetyl neuraminic acid or combinations thereof, and R 3 is H or N-acetyl neurami¬ nic acid in an amount of 0.01 to 15% (v/v) calculated on the total volume of the preparation. The nasal epithelial membrane consists of practically a single layer of epithelial cells (pseudostratified epi¬ thelium) and it is therefore even more suited for antigen and/or vaccine administration than other mucosal surfaces having squamous epithelial layers, such as the mouth, va¬ gina, etc. These surfaces, however, are also well suited for the application of antigens and/or vaccines with the delivery system according to the invention. The extensive network of blood capillaries under the nasal mucosa is - together with the high density of T and B cells - parti- cularly suited to provide a rapid recognition of the antigen and/or the vaccine, which may also provide a quick immunological response. For liquid compositions it is essential that the effective amount of the antigen and/or the vaccine can be admini¬ stered in a volume of less than about 300 ul for human subjects. A larger volume can be disagreeable to the pa¬ tient and will evidently drain out anteriorly through the nostrils or posteriorly toward the pharynx. The result is that a part of the antigen and/or the vaccine is lost from the absorption site. The volume is preferably from about 20 nl to about 125 nl and preferably administered into both nostrils. A variety of vehicle systems for the delivery of antigens and/or vaccines have been developed. The literature to date has suggested that uptake of antigens and/or vaccines from the nasal mucosa is frequently made possible by in¬ corporation of a special vehicle system into the formula¬ tion, adding certain amount of absorption enhancing agents or a certain amount of adjuvants. Much has been written regarding the potential use of various vehicles as drug delivery systems for intranasal administration. In such vehicle systems, the medicament is rapidly absorbed into the blood stream. One of the prob¬ lems encountered in using such vehicle systems is that the antigen and/or the vaccine is absorbed and degraded with¬ out recognition and, therefore, without stimulating an immunological response. The system according to the inven¬ tion describes a vaccine/antigen delivery system which provides a clear immunological response in spite of the short contact time inside the nasal cavity. A possible enhancement of the immunological response after mucosal administration of polyoxyethyl-35-castor oil, cap¬ rylic/capric acid glycerides and/or gangliosides together with an antigen or a vaccine has not been suggested any- where in the prior art. US patent No. 4,610,868 describes a lipid matrix carrier for parenteral administration of drugs. This system re¬ quires a lipid matrix carrier comprising a hydrophobic compound, an amphipathic compound and a bioactive agent with a globular structure of a diameter between 500 and 100,000 nm. Here the hydrophobic compound may comprise a mixture of glycerides and the amphipathic compound may comprise a sphingolipid. Furthermore, this formulation may be administered into the nasal area. However, this system is not acceptable as a nasal formulation, due to the rapid clearance inside the nose and the large globular struc¬ ture. Therefore, this system will be transferred into the stomach by the cilia before the bioactive agent is re- leased. US patent No. 4,985,242 describes an intranasally applic¬ able powdery pharmaceutical composition comprising a poly- peptide with physiological activity, a quaternary ammonium compound, and a lower alkyl ether of cellulose. Typical surfactants in this composition are polyoxyethylene sorbi- tan fatty acid esters. This powdery pharmaceutical compo¬ sition is stated to have an excellent preservability and chemical stability of the polypeptides. Further, when the composition is administered to the nasal cavity in the form of a spray, the polypeptides are absorbed effectively through the nasal mucosa. However, the surfactant concen¬ tration is critical since, on the one hand, high concen¬ trations lead to sticky preparations without powder cha- racteristics. On the other hand, low concentrations will not enable the induction of an immunological response. If the purpsose of US patent No. 4,985,242 had been to induce an immunological response, which is not the case, this would be regarded as a serious drawback when protein and peptide drugs were to be administered. These surfactants would therefore not be usable for the purpose of the pre¬ sent invention. Several other references relating to the use of a polyoxy¬ ethylene derivative of a sorbitan ester in nasal prepara- tions are known. However, no reference describes the sub¬ stance according to the invention as an adjuvant or as an immunomodulator. This effect is indeed surprising and un¬ expected. A novel method of administering the natural female sex hormones 170-oestradiol and progesterone as solutions, suspensions, gels and ointments, containing 1% to 2% Tween 80, is described in US Patent No. 4,315,925. From EP Patent No. 246,625 is known an aqueous steroid formulation for nasal administration of an anti-inflamma- toric steroid preparation containing propylene glycol, polyethylene glycol 400 and 1% to 4% Tween 20. EP Patent No. 242,643 describes an intranasal administration of drugs, especially insulin, using e.g. 0.01% to 0.5 % Tween 80 to reduce the nasal irritation by other absorption pro¬ moters. Finally, in PCT/AT87/00015 a sprayable, Tween-con- taining formulation for e.g. benzodiazepines is des¬ cribed. However, this formulation requires the use of a propeller gas. The present invention presents a new and significantly improved method for the administration of antigens/vac¬ cines, using the above new type of formulation. The method provides protective immune response in recipients of the antigen and/or the vaccine, both systemically and locally, which are elicited after intranasal immunization. The primary object of the invention is to provide an intranasal composition, which is capable of producing a high systemic immune response (humoral and cellular, main¬ ly of the IgG isotype) as well as locally produced anti- bodies of the secretory IgA isotype at mucosal surfaces without causing unacceptable damage to the nasal epithe¬ lial membrane. It is another object of the invention to provide a con- trolled delivery system for intranasal application, which is biocompatible with the mucus and which is capable of dissolving required amounts of antigens and/or vaccines in small volumes. According to an aspect of the invention the present de¬ livery system is also usable for other mammalian surfaces such as the vagina, eye, mouth, lungs, ear, genital tract, gastrointestinal tract, rectum, skin etc. As mentioned previously, the pharmaceutical preparation of the present invention is characterized by comprising one or more substances selected from (a) polyoxyethylene sorbitan monoesters, (b) polyoxy- ethylene glycerol triesters, (c) caprylic/capric acid glycerides, and (d) gangliosides. The preferred polyoxyethylene sorbitan monoester (a) is Polysorbate 20, which is a laurate ester of sorbitol and its anhydrides copolymerized with approximately 20 moles of ethylene oxide for each mole of sorbitol and sorbitol anhydrides. The polyoxyethylene glycol triester (b) is preferably Polyoxyl-35-castor oil. This compound is mainly the triricinoleate ester of ethoxylated (about 35 moles) gly- cerol with smaller amounts of polyethylene glycol ricino- leate and the corresponding free glycols. Polyoxyl-35- castor oil is commonly known as Cremophor EL. The caprylic/capric acid glycerides (c) are principally a mixture of mono-, di- and triglycerides in which the acid groups are only caprylic and capric acid groups. They are known commercially under the trade name Imwitor. The gangliosides (d) of the above formula IV are princi¬ pally a mixture of asialo-, monosialo-, disialo- and tri- sialogangliosides. The composition according to the invention may comprise one or more additional pharmaceutical excipients, selected among surfactants and absorption promoters, such as poly¬ oxyethylene alcohol ethers, bile salts and derivatives thereof, fusidic acid and derivatives thereof, oleic acid, lecithin, lysolecitines, Tween 21 to 85, etc, water ab- sorbing polymers, such as glycofurol, polyethylene glycol 200 to 7500, polyvinylpyrrolidone, propylene glycol or polyacrylic acid, gelatine, cellulose and derivatives, etc.; substances which inhibit enzymatic degradation, such as aprotinin, etc.; alcohols, such as ethanol, glycerol, benzyl alcohol, etc.; organic solvents such as ethyl ace¬ tate, benzyl alcohol, etc. ; hydrophobic agents, such as vegetable oil, soybean oil, peanut oil, coconut oil, maize oil, olive oil, sunflower oil, "Miglyols" or mixtures thereof, etc.; pH-controlling agents, such as nitric acid, phosphoric acid, acetic acid, citrates, etc.; preserva¬ tives and osmotic pressure controlling agents, such as glycerol, sodium chloride, methyl paraoxybenzoate, benzoic acid, etc.; liposome and/or emulsion formulations, such as lecitines, etc.; microencapsulated formulations; propel- lants, such as butane; water etc. The use of propellants is not compulsory in the preparation according to the invention. The pharmaceutical preparation of the invention may com¬ prise any antigens and/or vaccines. The vaccines may be selected among all the vaccines causing diseases in humans or animals. These include bacterial vaccines such as chla- mydia, cholera, diphtheria, haemophilus influenzae, lepro¬ sy, meningococcal, pertussis, pneumococcal, shigella, tetanus, tuberculosis, etc.; virus vaccines such as hepa- titis viruses, herpes viruses, human immunodeficiency viruses (HIV), influenza viruses, measles virus, mumps virus, parainfluenza virus, paramyxo viruses, polio virus, rabies viruses, respiratory syncytial viruses, rhinovirus types, rotavirus, rubella virus, etc., and parasite vac- cines such as vaccines for leishamaniasis, schistosomiasis and trypanosomiasis, which may be used to produce local and/or systemic antibodies. The invention is described in further detail in the fol- lowing examples. EXAMPLE I A tetanus vaccine formulation consists of (a) tetanus toxoid (22.5 ul), gangliosides (10.0 ul) and Tween-20 (7.5 ul); (b) tetanus toxoid (22.5 ul) and a solution of an Imwitor/cremophor mixture (1:1) (17.5 ul); (c) tetanus toxoid (22.5 ul) and isotonic saline (17.5 ul). Formula¬ tions a, b and c are administered intranasally to mice (2.5 ul / nostril) under i.p. nembutal anaesthesia. Each mouse received 1.5 Lf tetanus toxoid. Three weeks later the mice are boosted with the same formulations and one week after, they are sacrificed and serum and nasal wash antibodies are measured. The excess serum samples are furthermore measured in living animals receiving live tetanus toxoid in the neutralisation test. The following results were obtained: Formulation Blood IgG Nasal IgA Neutralisation Control (s.c. ) a) 1.09 105 0.5 Formulation a 2.45 625 0.5 Formulation b 1.54 1132 0.8 Formulation C 0.0007 30 0.000 a) Commercially available product, single administration. EXAMPLE II A diphtheria vaccine formulation consists of (a) diphthe¬ ria toxoid (7.5 ul), gangliosides (12.5 ul) and Tween-20 (20.0 ul); (b) diphtheria toxoid (7.5 ul), PBS-saline (12.5 ul) and a solution of an Imwitor/cremophor mixture (1:1) (20.0 ul); (c) diphtheria toxoid (7.5 ul) and iso- tonic saline (32.5 ul). Formulations a, b and c are ad¬ ministered intranasally to mice (2.5 ul / nostril) under i.p. nembutal anaesthesia. Each mouse received 1.5 Lf diphtheria toxoid. Three weeks later the mice are boosted with the same formulations and one week after they are sacrificed and serum and nasal wash antibodies are meas¬ ured. The excess serum samples are furthermore measured in the neutralisation test. The following results were ob¬ tained: Formulation Blood IgG Nasal IgA Neutralisation Control (s.c.) a) 0.354 34 0.012 Formulation a 0.004 36 0.025 Formulation b 2.22 352 0.020 Formulation c 0.0004 30 0.000 a) Commercially available product, single administration. EXAMPLE III An influenza vaccine formulation consists of (a) influenza virus vaccine (5.0 ul), gangliosides (10.0 ul), a solution of an Imwitor/cremophor mixture (1:1) (6.0 ul), distilled water (16.5 ul) and a PBS solution (2.5 ul); (b) influenza virus vaccine (5.0 ul) and isotonic saline (35.0 ul). The formulation was administered intranasally to mice (2.5 ul / nostril) under i.p. nembutal anaesthesia. Each mouse re¬ ceived 0.2 ug influenza HA. Four weeks later the mice were sacrificed and the serum HI titer measured. The following results were obtained: Formulation HI test Control (s.c. ) a) 1/80 Formulation a 1/160 Formulation b 1/20 a) Commercially available product. EXAMPLE IV A tetanus and diphtheria vaccine formulation consists of (a) tetanus toxoid (510 ul), diphtheria toxoid (169 ul), gangliosides (75 ul) and Tween-20 (750 ul); (b) tetanus toxoid (510 ul), diphtheria toxoid (169 ul) and a solution of an Imwitor/cremophor mixture (1:1) (220 ul). Six rab¬ bits were divided into 3 groups of 2 rabbits each (4 nos¬ trils in each group). Formulations a and b were admini- stered intranasally (50 ul into each nostril) under un- anaesthesized condition. Each rabbit received 18 Lf te¬ tanus toxoid and 18 Lf diphtheria toxoid. The last group served as control and received only a single intranasal dose of isotonic saline. The rabbits were sacrificed by intravenous injection of pentobarbital 3% h after dosing. Each nasal cavity was opened and individually evaluated macroscopically. The evaluator was blind as to the dosing scheme. The data show that the lesions observed were dis¬ tributed almost evenly over the control and the test groups. Small focal nature and anterior location of some lesions were obtained, corresponding to the abrasion from the tip of the applicatior pipette. No macroscopic dif¬ ference was observed between isotonic saline and the for¬ mulations a and b. EXAMPLE V Three solvents, phosphate buffered saline (PBS), capry¬ lic/capric acid glycerides (CCG) and polyoxyethylene sorbitan monoesters (PS), were mixed together in various concentrations in order to see their interrelationship (phase diagram). The figure shows that within certain con¬ centration rages an emulsion or a semisolid solution is achieved. CCG and PBS show a heteogeneous solution upon mixing when little or no PS is present in the system. Viscosity, bioadhesiveness, sprayability and homogenicity (in the case of an emulsion delivery system) may be con¬ trolled, dependent on the concentration of each substance. EXAMPLE VI A tetanus vaccine formulation consists of (a) tetanus toxoid (510 ul), gangliosides (75 ul), polyoxyethylene sorbitan monoesters (750 ul) and saline (169 ul); (b) com- mercially available tetanus/diphteria vaccine, adsorbed to aluminum hydroxide. Formulation a was administered intra¬ nasally to rabbits (50 ul/nostril) using no anaesthesia nor sedation, and formulation b was administered subcu- taneously. Each rabbit received 18 Lf tetanus toxoid and 18 Lf diphtheria toxoid. Three weeks later the rabbits received a booster of the same formulations. Weekly serum samples were collected from the marginal ear vein, and the samples were measured using the ToBi technique. The fol¬ lowing results were obtained (IU/ml) : Formulation 2 weeks 3 weeks 4 weeks a 0.034 1.012 0.847 b 0.477 1.572 1.456 EXAMPLE VII The synergistic effect between caprylic/capric acid glyce- rides (CCG) and polyoxyethylene sorbitan monoesters (PS) was determined as follows: Six diphtheria (1.5 Lf) vaccine formulations were made: (a) in phosphate buffered saline (PBS); (b) commercially available A1(0H) 3 adsorbed vaccine for subcutaneous in¬ jection; (c) in PBS solution containing 40% polysorbate 20; (d) in PBS solution containing 40% polysorbate 20 and 25% polyoxyethylene castor oil; (e) in 40% polysorbate 20 and 10% caprylic/capric acid glyceride (mono- and dϊ-gly- cerides); and (f) in 40% polysorbate 20, 25% polyoxyethy- lene castor oil and 10% caprylic/capric acid glyceride (mono- and di-glycerides). The formulations were admini¬ stered intranasally to mice (2.5 μl/nostril) under i.p. nembutal anaesthesia. Three weeks later the mice received a booster containing the same formulations, and a further week later they were sacrified and serum antibodies were measured. The following results were obtained: Formulations Diphth. IgG a 0.0004 b 0.354 c 0.448 d 0.127 e 7.3 0.115 It appears that neither PS nor CCG alone can provide a satisfactory effect. This is only the case with combina- tions of PS and CCG. EXAMPLE VIII In this example the synergistic effect between caprylic/ capric acid glycerides (CCG) and polyoxyethylene sorbitan monoesters (PS) was investigated further. Seven influenza A vaccine formulations were made: (a) in phosphate buffered saline (PBS); (b) in PBS solution con- taining 25% polyoxyethylene castor oil; (c) in PBS solu¬ tion containing 25% polyoxyethylene castor oil and 10% caprylic/capric acid glyceride (mono- and di-glycerides); (d) in PBS solution containing 40% polysorbate 20; (e) in PBS solution containing 40% polysorbate 20 and 25% poly¬ oxyethylene castor oil; (f) in 40% polysorbate 20 and 10% caprylic/capric acid glyceride ( mono- and di-glycerides); and (g) in 40% polysorbate 20, 25% polyoxyethylene castor oil and 10% caprylic/capric glyceride (mono- and di-gly¬ cerides). The formulations were administered intranasally to mice (2.5 μl/nostril) under i.p. nembutal anaesthesia. Three weeks later the mice received a booster, containing the same formulations, and a further week later they were sacrificed and the serum antibodies were measured. The following results were obtained: Formulation IgG a 0.072 b 0.053 c 0.073 d 0.114 e 0.038 f 0.354 g 0.037 Caprylic/capric acid glycerides were not tested alone, since they are insoluble in water. EXAMPLE IX This example illustrates the selection of the optimal CCG and PS concentration. Seven diphtheria vaccine formulations were made: (a) in phosphate buffered saline (PBS); (b) in PBS solution con¬ taining 35% polysorbate 20; (c) in PBS solution containing 57.5% polysorbate 20; (d) in PBS solution containing 35% polysorbate 20 and 10% caprylic/capric acid glyceride ( mono- and di-glycerides); (e) in PBS solution containing 57.5% polysorbate 20 and 10% caprylic/capric acid glyce- ride (mono- and di-glycerides); (f) in PBS solution con¬ taining 35% polysorbate 20 and 24% caprylic/capric acid glyceride (mono- and di-glycerides); and (g) in 57.5% polysorbate 20 and 24% caprylic/capric acid glyceride (mono- and di-glycerides). The formulations were admini- stered intranasally to mice (2.5 μl/nostril) under i.p. nembutal anaesthesia. Three weeks later the mice received a booster, containing the same formulations, and one further week later they were sacrificed and the serum antibodies were measured. The following results were ob- tained: Formulation IgG a 0.365 b 1.22 c 0.092 d 9.65 e 2.33 f 1.31 g 26.6 Caprylic/capric acid glycerides were not tested alone, since they are insoluble in water. EXAMPLE X The selection of the optimal CCG and PS concentration is further illustrated in this example. Seven diphtheria and tetanus vaccine formulations were made by using fixed caprylic/capric acid glyceride ( mono- and di-glycerides) concentration (10%) but variable poly¬ sorbate 20 (mono-ester) concentration, ranging from 28% (a) with 2% increments up to 40% (g). The formulations were administered intranasally to mice (2.5 μl/nostril) under i.p. nembutal anaesthesia. Three weeks later the mice received a booster, containing the same formulations, and one additional week later they were sacrificed and the serum antibodies were measured. The following results were obtained: Formulation Diphth. IgG Tetan. IgG a 0 0..0077 0.04 b 0.17 0.04 c 0.10 0.02 d 0.16 0.03 e 1.60 0.01 ff 1 1-.2255 0.06 g 0.27 0.004 EXAMPLE XI This example concerns the selection of polyoxyethylene fatty acid esters. Such polyoxyethylene fatty acid esters are found as mono- and tri-esters. Diphtheria toxoids were formulated in the following different compositions: (a) in isotonic phosphate buffered saline (PBS); (b) in PBS solu¬ tion containing 47% polysorbate 80 (tri-ester); and (c) in PBS solution containing 47% polysorbate 20 (mono-ester). The formulations were administered intranasally to mice (2.5 μl/nostril) under i.p. nembutal anaesthesia. Four weeks later the mice were sacrificed and the serum anti¬ bodies were measured. The following results were obtained: Formulation IgG a 0.001 b 0.002 c 0.006 EXAMPLE XII The selection of glyceride esters was performed as follows: Six tetanus (1.5 Lf) and diphtheria (1.5 Lf) vac¬ cine formulations were made. The formulations were admini¬ stered intranasally to mice (2.5 μl/nostril) under i.p. nembutal anaesthesia. Four weeks later the mice were sac- rificed and serum and nasal wash antibodies were measured, The following results were obtained: Formulation Diphth. IgG Tetan. IgG Negative control 0.0013 0.0078 C 8 an d 10 diglvceride ester (Miglyol 829)(3.5%) 0.0003 0.0030 Cg and 10 mono-diglyceride ester (Imwitor 742)(7%) 0.0027 0.2580 C 16 triglyceride ester (Dynasan 116)(2.5%) 0.0014 0.0057

Claims: P a t e n t C l a i m s 1. A pharmaceutical preparation for topical administra- tion of antigens and/or vaccines to mammals via a mucosal membrane, CHARACTERIZED by comprising one or more adju¬ vants/vehicles selected from (a) polyoxyethylene sorbitan monoesters of the general formula H0( H 2 C(0C 2 H 4 ) z R wherein R is selected among laurate, palmitate, stearate and oleate, and wherein the sum of w, x, y and z is 4, 5 or 20; (b) polyoxyethylene castor oil produced by reacting 1 mole of castor oil or hydrogenerated castor oil with 10-45 moles of ethylene oxide; (c) caprylic/capric acid glycerides of the general formula R α -0-CH 2 -CH-CH 2 -0-R α I OR 1 wherein each R 1 independently is H or a o -C 10 acyl group containing 1-6% free glycerol, 45-50% monogly- cerides, 30-40% diglycerides and 5-9% triglycerides, and (d) gangliosides of the general formula R 2 -Gal-Glc-Cer I R 3 -NeuAc wherein Gal is galactose, Glc is glucose, Cer is ceramide (N-fatty acyl sphingosine) and NeuAc is N- acetyl neuraminic acid (sialic acid), and wherein R 2 may be one or more substances selected among N-acetyl galactosamine, galactose, N-acetyl neuraminic acid or combinations thereof, and R 3 is H or N-acetyl neura- minic acid in an amount of 0.01 to 15% (v/v) calculated on the total volume of the preparation. 2. A pharmaceutical preparation according to claim 1, CHARACTERIZED in that the antigens and/or vaccines are selected among bacterial vaccines such as chlamydia, cholera, diphtheria, haemophilus influenzae, leprosy, meningococcal, pertussis, pneumococcal, shigella, tetanus, tuberculosis, etc.; virus vaccines such as hepatitis viruses, herpes viruses, human immunodeficiency viruses (HIV), influenza viruses, measles virus, mumps virus, parainfluenza virus, paramyxo viruses, polio virus, rabies viruses, respiratory syncytial viruses, rhinovirus types, rotavirus, rubella virus, etc., and parasite vaccines such as vaccines for leishamaniasis, schistosomiasis and trypa- nosomiasis, which may be used to produce local and/or sys¬ temic antibodies, or mixtures thereof. 3. A pharmaceutical preparation according to claim 1 or 2, CHARACTERIZED by further comprising at least one com- pound selected from the group consisting of surfactants and/or absorption promoters, water absorbing polymers, oils, emulsions, liposomes, substances inhibiting enzyma¬ tic degradation, alcohols, organic solvents, water, hydro- phobic agents, pH-controlling agents, preservatives and osmotic pressure controlling agents, cyclodextrines and propellants or mixtures thereof. 4. A pharmaceutical preparation according to any of the claims 1-3, CHARACTERIZED in that the application is directed to the mucosa of the nose, mouth, eye, ear, va¬ gina or rectum. 5. A pharmaceutical preparation according to claim 4, CHARACTERIZED in that the application is directed to the mucosa of the nose. 6. A vaccine or antigen formulation, CHARACTERIZED in that 100 ml of the formulation contains: from 0.01 to 90 ml active vaccine/antigen component, from 0.01 to 75 ml caprylic/capric acid glyceride, from 0.1 to 95 ml polyoxyethylene sorbitan monoesters and optionally one or more adjuvants or excipients. 7. A vaccine or antigen formulation, CHARACTERIZED in that 100 ml of the formulation contains: from 0.01 to 90 ml active vaccine/antigen component, from 0.01 to 90 ml gangliosides, from 0.1 to 95 ml polyoxyethylene castor oil or polyoxyethylene sorbitan monoesters, from 0.1 to 75 ml caprylic/capric acid glycerides and optionally one or more adjuvants or excipients. 8. A vaccine or antigen formulation, CHARACTERIZED in that 100 ml of the formulation contains from 0.01 to 90 ml active vaccine/antigen component, from 0.01 to 90 ml gangliosides and/or polyoxyethylene castor oil, from 0.1 to 95 ml polyoxyethylene sorbitan monoesters, from 0.1 to 75 ml caprylic/capric acid glycerides, from 0.01 to 99 ml PBS/saline, from 0.01 to 90 ml distilled water and optionally one or more adjuvants or excipients. 9. The use of compounds selected from (a) polyoxyethylene sorbitan monoesters of the general formula H 2 C(OC 2 H 4 ) z R wherein R is selected among laurate, palmitate, stearate and oleate, and wherein the sum of w, x, y and z is 4, 5 or 20; (b) polyoxyethylene castor oil produced by reacting 1 mole of castor oil or hydrogenerated castor oil with 10-45 moles of ethylene oxide; (c) caprylic/capric acid glycerides of the general formula R 1 -0-CH 2 -CH-CH 2 -0-R 1 OR 1 wherein each R 1 independently is H or a Cg-C 1Q acyl group containing 1-6% free glycerol, 45-50% monogly- cerides, 30-40% diglycerides and 5-9% triglycerides, and (d) gangliosides of the general formula R 2 -Gal-Glc-Cer I R 3 -NeuAc wherein Gal is galactose, Glc is glucose, Cer is ceramide (N-fatty acyl sphingosine) and NeuAc is N- acetyl neuraminic acid (sialic acid), and wherein R 2 may be one or more substances selected among N-acetyl galactosamine, galactose, N-acetyl neuramininic acid or combinations thereof, and R 3 is H or N-acetyl neuraminic acid in an amount of 0.01 to 15% (v/v) calculated on the total volume of the preparation, as adjuvants/vehicles in pharmaceutical preparations for the topical administration of antigens and/or vaccines to mammals.

Inventors: GIZURARSON SVEINBJOERN, HERON IVER, GIZURARSON, SVEINBJOERN, HERON, IVER
Applicants: GIZURARSON SVEINBJOERN, HERON IVER, LYFJATHROUN H F, STATENS SERUMINSTITUT, GIZURARSON, SVEINBJOERN, HERON, IVER, LYFJATHROUN H.F.
Application year: 1994
Main classification: A61K39
IPC codes: A61K9, A61K39, A61K47, A61P37